Evidence map›Paper›PMID 41258231›Full record

ArticleCommunications medicine2025

More evidence is needed to improve molecular HIV surveillance for cluster detection and response.

Anne Lr Schuster, Juli Bollinger, Gail Geller, Susan J Little, Sanjay R Mehta, Travis Sanchez, Jeremy Sugarman, John Fp Bridges

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anne Lr SchusterDepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA. anne.schuster@osumc.edu.ORCID http://orcid.org/0000-0003-4391-1712
Juli BollingerBerman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6850-8562
Gail GellerBerman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
Susan J LittleDivision of Infectious Disease, University of California San Diego, San Diego, CA, USA.ORCID http://orcid.org/0000-0002-7645-9737
Sanjay R MehtaDivision of Infectious Disease, University of California San Diego, San Diego, CA, USA.
Travis SanchezDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Jeremy SugarmanBerman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-7022-8332
John Fp BridgesDepartment of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA.

Funding

NIMH NIH HHS R01 MH124590U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01MH124590
6 · The paper itself

Abstract

backgroundMolecular HIV surveillance (MHS) is used in the U.S. to inform public health prevention and intervention activities aimed at helping end the HIV epidemic. Its application in this context is currently challenged by ethical, legal, and social concerns, with gaps in understanding how end users weigh these issues. We sought to identify the preferences of MHS end users for improving MHS.

methodsEnd users completed 12 choice experiment tasks evaluating five attributes of MHS for cluster detection and response. We generated a choice model using conditional logit and report results as relative attribute importance scores, comparing them to attitudinal data from close-ended questions. Responses to open-ended questions provide additional context on areas for MHS improvement.

resultsWe report findings from 55 of 90 potential end-users who felt capable and agreed to participate. End users include researchers (n = 28) and public health practitioners (n = 27); their preferences do not differ significantly (p = 0.174) so their responses are combined. The highest weight is placed on certainty of MHS benefit (38%), followed by depth of HIV sequence sampling (26%). Lower weight is given to reducing stigma (20%) and personalized inferences (10%) and communication (6%). End users highlight improving MHS through implementation support, community engagement, transparent communication, intervention assistance, risk minimization, and impact assessment; researchers stress the need for better data access.

conclusionsEnd users place the highest value on having more evidence of MHS benefits. Improving MHS requires attention to implementation support, community engagement, transparent communication, intervention assistance, risk mitigation, impact assessment, and data access.

Identifiers

PMID41258231
PMCPMC12669793

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.